September 30, 2009 (FinancialWire) — Amarillo Biosciences, Inc. (OTCBB: AMAR) (Current Market Cap: $11.69 Mil.) has appointed Bernard Cohen as chief financial officer. He replaces Gary Coy, who will assist the company with SEC filings as a consultant.

Cohen was previously director of finance and data base manager at Harrington Regional Medical Center in Amarillo. Before that, he held various executive positions at Colbert’s department store of Amarillo holding the position of CEO, VP and controller, and personnel director.

Amarillo, Texas-based Amarillo Biosciences is a biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 7% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments.

The company’s primary focus is R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.